Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen

Clinical Chemistry - Tập 44 Số 11 - Trang 2281-2289 - 1998
Christian Rosenquist1, Christian Fledelius1, Stephan Christgau1, B.J. Pedersen1, M. Bonde1, Per Qvist1, Claus Christiansen2
1Osteometer BioTech A/S, Osteopark, Herlev Hovedgade 207, DK-2730 Herlev, Denmark
2Center for Clinical and Basic Research, Ballerup Byvej 222, DK-2750 Ballerup, Denmark

Tóm tắt

AbstractWe have developed a two-site ELISA for measurement in serum of bone-related degradation products derived from C-terminal telopeptides of type I collagen. The assay is based on the application of two highly specific monoclonal antibodies against the amino acid sequence of AHD-β-GGR, where the aspartic acid residue (D) is β-isomerized. In a one-step incubation procedure, the degradation products containing cross-linked diisomerized EKAHD-β-GGR peptides are captured by a biotinylated antibody and a peroxidase-conjugated antibody. The generated complex is then bound to the streptavidin surface via the biotin conjugate. Desalted urinary antigens are used for standardization, and parallelism is observed with serum samples. Results are obtained in <2.5 h, and both inter- and intraassay imprecision are <8%. The serum CrossLaps™ concentration was 1748 ± 740 pmol/L (mean ± SD) in premenopausal women (n = 65) and 2952 ± 1325 pmol/L in a group of healthy postmenopausal women (n = 169). The Serum CrossLaps One Step ELISA was capable of detecting a highly significant (P <0.001) effect of hormone replacement therapy in a retrospective study involving 22 postmenopausal women.

Từ khóa


Tài liệu tham khảo

1988, Annu Rev Cell Biol, 4, 552

1988, Anal Biochem, 169, 197, 10.1016/0003-2697(88)90274-6

1994, J Bone Miner Res, 9, 1643, 10.1002/jbmr.5650091019

1992, J Bone Miner Res, 7, 1251, 10.1002/jbmr.5650071119

1994, Clin Chem, 40, 2022, 10.1093/clinchem/40.11.2022

1995, J Clin Endocrinol Metab, 80, 864

1994, J Clin Endocrinol Metab, 79, 780

1993, Clin Chem, 39, 635, 10.1093/clinchem/39.4.635

1997, J Bone Miner Res, 12, 1028, 10.1359/jbmr.1997.12.7.1028

1997, Clin Chem, 43, 2058, 10.1093/clinchem/43.11.2058

1992, J Histochem Cytochem, 40, 231, 10.1177/40.2.1552166

1979, J Immunol, 123, 1548, 10.4049/jimmunol.123.4.1548

1991, J Histochem Cytochem, 39, 749, 10.1177/39.6.1674516

1994, Clin Chem, 40, 1258, 10.1093/clinchem/40.7.1258

1997, J Biol Chem, 272, 9755, 10.1074/jbc.272.15.9755

1974, Histochem Cytochem, 22, 1084, 10.1177/22.12.1084

1991, Interferographs. User’s guide to interferences in clinical chemistry instruments, 8

1987, Guide for personal computers, 941

1997, Scand J Clin Lab Investig, 57, 73

1995, Annu Rev Biochem, 64, 403, 10.1146/annurev.bi.64.070195.002155

1995, N Engl J Med, 332, 305, 10.1056/NEJM199502023320506

1983, J Lab Clin Med, 102, 470

1994, J Clin Endocrinol Metab, 79, 780

1995, Am J Med, 98, 29S, 10.1016/S0002-9343(05)80042-7

1998, Clin Chem, 44, 2302

1994, Bone Miner, 24, 81, 10.1016/S0169-6009(08)80147-X

1995, Calcif Tissue Int, 57, 25, 10.1007/BF00298992

1995, Clin Chem, 41, 1592, 10.1093/clinchem/41.11.1592

1994, Calcif Tissue Int, 54, 30, 10.1007/BF00316286

1997, J Bone Miner Res, 12, S583

Thông tin
Thông tin xuất bản

Clinical Chemistry

Tập 44 Số 11

2281-2289

Thông tin tác giả